AgomAb Therapeutics NV - ADRs representing one common share

Revenue, earnings and FCF predictability are very low. Both lead assets are pre‑pivotal and outcomes are binary. The NOV‑ERA Phase 2b study introduces a novel primary endpoint (endoscopic passability) even though FDA alignment reduces regulatory risk.

AGMB‑447 enters a highly competitive and failure‑prone IPF field despite encouraging Phase 1 proof‑of‑mechanism. While the company has communicated timelines for Phase 2b/2 initiations in 2H26 and expects OLE and Phase 1b readouts in 2H26, the fundamental uncertainty remains high until robust, reproducible mid‑ to late‑stage efficacy data exist.